Longrange

RSS

eprinomectin

Refused
This medicine was refused authorisation for use in the European Union.

Overview

On 21 June 2018, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Longrange, intended for the treatment and prevention of parasitic infections in cattle.

The company that applied for authorisation is Merial. The company requested a re-examination of the initial opinion. After considering the grounds for this request, the CVMP re-examined the opinion and confirmed the refusal of the marketing authorisation on 11 October 2018.

This EPAR was last updated on 21/03/2019

Application details

Product details
Name
Longrange
Active substance
eprinomectin
International non-proprietary name (INN) or common name
eprinomectin
Species
Cattle
Application details
Marketing-autorisation applicant
Merial

Assessment history

How useful was this page?

Add your rating